Oral Steroids for Brachial Neuritis: Dose and Duration
Based on the best available evidence, oral prednisone 1 mg/kg/day (maximum 60 mg daily) should be initiated within the first month of symptom onset and continued for 10-14 days, followed by a gradual taper over a similar period.
Evidence Base and Rationale
The recommendation is primarily derived from a retrospective observational study of 50 patients with neuralgic amyotrophy (brachial neuritis) treated with prednisolone in the acute phase 1. This study demonstrated that patients treated with oral prednisolone experienced:
- Faster pain relief: Median time to initial pain relief was 12.5 days versus 20.5 days in untreated controls
- Earlier strength recovery: 18% recovered strength in the first month versus 6.3% in controls (p = 0.011)
- Better 12-month outcomes: 12% fully recovered within 1 year versus 1% in controls (p<0.001), with 44% reporting "good" outcomes versus 10.7% (p<0.001)
A Cochrane systematic review confirms this is the only substantial evidence available, noting that "oral prednisone given in the first month after onset can shorten the duration of the initial pain and leads to earlier recovery in some patients" 2.
Specific Dosing Protocol
Initial Treatment Phase
- Dose: 1 mg/kg/day oral prednisone (usual maximum 60 mg daily) 3
- Timing: Administer as a single morning dose before 9 AM to minimize HPA axis suppression 3
- Duration: Full dose for 7-14 days
Tapering Phase
- After 4 days at maximum dose, taper by 10 mg every 2 days 4
- Total treatment duration including taper: approximately 2-4 weeks
- Critical: Avoid abrupt discontinuation 3
Timing Considerations
Treatment must be initiated within the first month of symptom onset for optimal benefit 1, 2. The earlier treatment begins, the better the outcomes. Patients presenting beyond 1 month may have limited benefit from corticosteroids.
Monitoring and Side Effects
In the observational study, 20% of patients reported side effects, but none required treatment discontinuation 1. Common short-term adverse effects include:
- Hyperglycemia
- Weight gain
- Sleep disturbance
- Increased appetite
These are generally acceptable and manageable for the short 10-14 day course recommended 4.
Important Clinical Caveats
When to Use Lower Doses
Consider starting at the lower end of the dosing range (0.5-0.75 mg/kg) in patients with:
- Diabetes mellitus
- Osteoporosis
- Glaucoma
- History of peptic ulcer disease
- Psychiatric conditions
Adjunctive Measures
- GI prophylaxis: Consider proton pump inhibitor if risk factors for peptic ulcer 5
- Physical therapy: Should be initiated concurrently and continued throughout recovery 6
- Pain management: NSAIDs or other analgesics may be needed as adjuncts
Evidence Limitations
The current evidence base is limited to one retrospective observational study 1. No randomized controlled trials exist 2. However, given the:
- Substantial clinical benefit observed (44% good outcomes vs 10.7%)
- Acceptable short-term safety profile
- Lack of alternative effective treatments
- Theoretical immunomodulatory mechanism fitting the disease pathophysiology
The risk-benefit ratio favors treatment in the acute phase, particularly within the first 2-4 weeks of symptom onset.
What NOT to Do
- Do not use doses >60 mg/day: No evidence of additional benefit and increased risk of adverse effects
- Do not use prolonged courses: Beyond 2-4 weeks total duration is not supported by evidence
- Do not delay treatment: Efficacy diminishes significantly after the first month
- Do not stop abruptly: Always taper to avoid adrenal insufficiency 3
Long-term Prognosis
Even with corticosteroid treatment, patients should be counseled that complete recovery may take months to years 7, 6. Many patients experience residual symptoms including pain, weakness, and fatigue. A multidisciplinary approach emphasizing motor coordination, energy conservation, and behavioral modification is recommended for persistent symptoms 6.